Wrap Text
TR-1: Standard form for notification of major holdings
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company", or the "Group")
04 March 2020
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS
1a. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are at- Mediclinic International plc
tachedii:
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
Name Genesis Investment Management, LLP
City and country of registered office (if applicable) 21 Grosvenor Place, London
4. Full name of shareholder(s) (if different from 3.)v
Name N/A
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or 28th February 2020
reachedvi:
6. Date on which issuer notified (DD/MM/YYYY): 04th March 2020
7. Total positions of person(s) subject to the notification obligation
% of voting rights
% of voting rights through financial in- Total number of
attached to shares struments Total of both in % voting rights of
(total of 8. A) (total of 8.B 1 + 8.B (8.A + 8.B) issuervii
2)
Resulting situation 4.98% 4.98% 737,243,810
on the date on
which threshold
was crossed or
reached
Position of previ-
ous notification (if 6.76% 6.76%
applicable)
8. Notified details of the resulting situation on the date on which the threshold was crossed or
reachedviii
A: Voting rights attached to shares
Class/type of Number of voting rightsix % of voting rights
shares
ISIN code (if possi- Direct Indirect Direct Indirect
ble) (Art 9 of Directive (Art 10 of Di- (Art 9 of Directive (Art 10 of Di-
2004/109/EC) rective 2004/109/EC) rective
(DTR5.1) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.2.1) (DTR5.2.1)
GB00B8HX8Z88 36,733,699 4.98%
SUBTOTAL 8. A 36,733,699 4.98%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Number of voting
Expira- rights that may be ac-tion
Type of financial datex Exercise/ quired if the instru- % of voting
instrument Conversion Periodxi ment is rights
exercised/converted.
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive
2004/109/EC (DTR5.3.1.1 (b))
Exercise/ Physical or
Type of finan- Expiration Conversion cash Number of % of voting
cial instrument datex Period xi settlementxii voting rights rights
SUBTOTAL
8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity
and does not control any other undertaking(s) holding directly or indirectly an interest in the (under-
lying) issuerxiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal
entityxiv (please add additional rows as necessary)
% of voting rights
% of voting rights if it through financial in- Total of both if it
equals or is higher struments if it equals equals or is higher
than the notifiable or is higher than the than the notifiable
Namexv threshold notifiable threshold threshold
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional informationxvi
Place of completion London, England
Date of completion 28 th February 2020
About Mediclinic International plc
Mediclinic is an international private healthcare services group, established in South Africa in 1983, with
divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of
care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare
services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
As at 1 February 2020, Mediclinic comprised 77 hospitals, five sub-acute hospitals, 14 day case clinics and
22 outpatient clinics. Hirslanden operated 17 hospitals, two day case clinics and three outpatient clinics in
Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations included 53 hospitals
(three of which in Namibia), five sub-acute hospitals and 10 day case clinics (four of which operated by
Intercare) across South Africa, and more than 8 500 inpatient beds; and Mediclinic Middle East operated
seven hospitals, two day case clinics and 19 outpatient clinics with more than 900 inpatient beds in the
United Arab Emirates.
The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with sec-
ondary listings on the JSE Ltd ("JSE") in South Africa and the Namibian Stock Exchange ("NSX") in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 04-03-2020 05:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
